Mankai Ju

Tianjin, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Erratum to: "Multilevel defects in the hematopoietic niche in essential thrombocythemia".

Erratum to: "Multilevel defects in the hematopoietic niche in essential thrombocythemia".

Journal: Haematologica

Published: June 01, 2026

External validation of the AAA+ survival model in a large Chinese cohort with essential thrombocythaemia.

External validation of the AAA+ survival model in a large Chinese cohort with essential thrombocythaemia.

Journal: British journal of haematology

Published: April 16, 2026

Clinical heterogeneity in congenital factor XII deficiency: Coexisting risk factors in thrombotic and bleeding events.

Clinical heterogeneity in congenital factor XII deficiency: Coexisting risk factors in thrombotic and bleeding events.

Journal: British journal of haematology

Published: February 24, 2026

An Ex Vivo Pharmacodynamic Study of KN057, a Tissue Factor Pathway Inhibitor Neutralizing Antibody, in Plasma Samples From Patients With Haemophilia or VWD3.

An Ex Vivo Pharmacodynamic Study of KN057, a Tissue Factor Pathway Inhibitor Neutralizing Antibody, in Plasma Samples From Patients With Haemophilia or VWD3.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: January 26, 2026

Long-term efficacy and safety of low-dose rituximab in immune thrombocytopenia: a multicentre, prospective, open-label, randomised controlled trial.

Long-term efficacy and safety of low-dose rituximab in immune thrombocytopenia: a multicentre, prospective, open-label, randomised controlled trial.

Journal: Annals of hematology

Published: November 25, 2025

Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial.

Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial.

Journal: EClinicalMedicine

Published: November 05, 2025

Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.

Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.

Journal: BMJ (Clinical research ed.)

Published: October 21, 2025

The effectiveness and safety of various treatments for hemophilia in China: a literature review and evidence mapping.

The effectiveness and safety of various treatments for hemophilia in China: a literature review and evidence mapping.

Journal: Hematology (Amsterdam, Netherlands)

Published: October 06, 2025

Bone marrow proteomic profiling reveals TMEM109 as a biomarker for relapse in thrombotic thrombocytopenic purpura.

Bone marrow proteomic profiling reveals TMEM109 as a biomarker for relapse in thrombotic thrombocytopenic purpura.

Journal: Journal of thrombosis and haemostasis : JTH

Published: July 24, 2025

Sabotaged Integral HSC Heterogeneity Underlies Essential Thrombocythemia Development.

Sabotaged Integral HSC Heterogeneity Underlies Essential Thrombocythemia Development.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: March 24, 2025

CDKN1A as a potential target for Eltrombopag treatment in ITP and its regulation of the communication between macrophages and transitional B cells in ITP.

CDKN1A as a potential target for Eltrombopag treatment in ITP and its regulation of the communication between macrophages and transitional B cells in ITP.

Journal: Annals of hematology

Published: March 04, 2025

Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials.

Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials.

Journal: Nature medicine

Published: March 02, 2025

Showing 1-12 of 40

Last Updated: 09/26/2026